Cessatech Begins CT001 Shipments to US Hospitals
Cessatech A/S has completed the initial U.S. commercial supply of CT001 and is commencing shipments to selected hospitals. Launch activities for the drug have now begun in the United States.
Cessatech A/S announced that the first commercial supply of its CT001 product has been released by its U.S. manufacturing partner, STAQ Pharma. This release makes the drug, CT001 (sufentanil/ketamine nasal spray), available for shipment to initial hospitals in the United States.
The availability of the commercial supply enables Cessatech to commence launch activities at selected U.S. hospitals. CT001 is a product developed by Cessatech, a late-stage specialty pharmaceutical company focused on hospital medicines for children.
The company's focus is on developing and commercializing hospital medicines specifically for pediatric patients. Cessatech aims to improve the treatment of children in hospital settings by providing suitable formulations.
Cessatech has not provided further details regarding the specific hospitals receiving the initial shipments or a broader rollout timeline for CT001 in the U.S. market.